Navigation Links
Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
Date:12/6/2011

IRVINE, Calif. and AMSTERDAM, Dec. 6, 2011 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that leading company researchers will present data from multiple studies in five poster presentations at the 2011 San Antonio Breast Cancer Symposium (SABCS).  The San Antonio Breast Cancer Symposium, one of the premiere conferences in breast cancer research worldwide, takes place December 6th – 10th, 2011.

Agendia's studies to be presented at SABCS 2011 will illustrate the broad predictive power of Agendia's Symphony™ breast cancer suite of molecular diagnostic tests led by MammaPrint®, the first and only FDA-cleared breast cancer recurrence test on fresh tissue. The suite, which also includes BluePrint®, TargetPrint® and TheraPrint®, provides a comprehensive decision support system, enabling physicians to determine whether a given breast cancer patient is likely to benefit from hormonal therapy, chemotherapy or targeted therapies. 

Full study results will be presented at the following poster sessions:

Date: Wednesday, December 7th
Time: 5:00pm – 7:00pm
Poster presentation (P1-06-20): Response to Neo-Adjuvant Chemotherapy and Outcomes for I-SPY 1 Patients Stratified by the 70-Gene Prognosis Signature (MammaPrint) and Molecular Subtyping (BluePrint)
Lead authors: Gluck S, de Snoo F, Tian S, Glas A, van 't Veer L. Miller School of Medicine, University of Miami, Miami, FL; Agendia, Amsterdam, Netherlands; HDFC Cancer Center, UCSF, San Francisco, CA.

Date: Wednesday, December 7th
Time: 5:00pm – 7:00pm
Poster presentation (P1-07-06): High Concordance of Protein (by IHC), Gene (by FISH; HER-2 Only) and Microarray Readout (by TargetPrint) of ER/PR/HER2: Results from the MINDACT Trial
Lead authors: Viale G, Bogaerts J, van't Veer L, Rutgers E, Piccart M, de Snoo F, Engelen K, Russo L, Dell'Orto P, Glas A, Cardoso F, on behalf of the TRANSBIG Consortium & the MINDACT Investigators. European Institute of Oncology, Milan, Italy; European Organisation of Research and Treatment of Cancer, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, Netherlands; Institute Jules Bordet, Brussels, Belgium; AgendiaNV, Amsterdam, Netherlands; Champalimaud Cancer Center, Lisboa, Portugal.

Date: Thursday, December 8th
Time: 5:00pm – 7:00pm
Poster presentation (OT2-03-02): Prospective Neo-Adjuvant Registry Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST)
Lead authors: Whitworth P, Beitsch P, Gittleman M, Akbari S. Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA.

Date: Thursday, December 8th
Time: 5:00pm – 7:00pm
Poster presentation (P3-04-06): Comparison of MammaPrint, BluePrint, and TargetPrint with Clinical Parameters in Patients with Breast Cancer: Findings from a Prospective United States Cohort
Lead authors: Nguyen B, Sinha R, Kerlin D, Barone J, Garcia A, Yao K, Rivera E, Stork-Sloots L, Deck K. Long Beach Memorial Health Care, Long Beach, CA; Rockwood Clinic, Spokane, WA; John Muir, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; University of Southern California, Los Angeles, CA; North Shore University Health System, Chicago, IL; The Methodist Hospital/Weill Cornell University, Houston, TX; Agendia Inc, Irvine, CA; Saddleback Memorial Medical Center, Laguna Hills, CA.

Date: Friday, December 9th
Time: 5:00pm – 7:00pm
Poster presentation (P5-11-09): High Concordance for Microarray Based Determination of ER, PR and HER2 Receptor Status and Local IHC/FISH Assessment Worldwide in 749 Patients
Lead authors: Wesseling J, Cusumano G, Tinterri C, Sapino A, Zanconati F, Lutke-Holzik M, Nguygen B, Deck K, Querzoli P, Perin T, Giardina C, Seitz G, Guinebretiere J, Barone J, Watanabe T. Netherlands Cancer Institute, Amsterdam, Netherlands; CHC, Liege, Belgium; Instituto Clinico Humanitas, IRCCS, Rozzano, Italy; Universita di Torino, Torino, Italy; Universita di Trieste, Trieste, Italy; Medisch Spectrum Twente, Enschede, Netherlands; Locg Beach Memorial Health Care, Loch Beach, CA; Saddleback Memorial Medical Center, Laguna Hills, CA; Instituto di Patologia, Universita di Ferrara, Ferrara, Italy; Centro di Riferimento Oncologico, Aviano, Italy; Instituto di Anatomia Patologica, Iniverstita degli Studi di Bari, Bari, Italy; Klinikum Bamberg, Bamberg, Germany; Centre Rene Huguenin, Saint-Cloud, France; Comprehensive Breast Care and Sharp Memorial Hospital, San Diego, CA; Hamamatsu Oncology Center, Hamamatsu, Japan.

About Agendia:

Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay for fresh tissue, as well as BluePrint­­, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay, and TheraPrint, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony suite of breast cancer tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.

For further information, please contact:


Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300 ext. 111
E-mail: todd@ricochetpr.com

 


'/>"/>
SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
2. Agendia Successfully Completes Bi-Annual FDA Inspection
3. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
4. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
5. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
6. Agendia Raises US $23 Million in Series E Financing
7. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
8. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
9. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
10. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
11. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols and ... from around the world. , The new GSCG clinic is headed by ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model ... the option of joining or renewing through an organizational ... staff size, every employee in any size association or ... all available member benefits.   John H. ... options will allow organizations of any size and their ...
(Date:2/10/2016)... Austin, Texas (PRWEB) , ... February 10, 2016 ... ... research centers across three states, announced today the promotion of two long-standing principal ... and Chief of Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced ... On Azure, Arvados provides capabilities for managing and processing genomic and health data ... from major institutions collecting and analyzing genomic data,” said Adam Berrey chief executive ...
Breaking Biology Technology:
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... February 3, 2016 --> ... research report "Automated Fingerprint Identification System Market by Component ... Application (Banking & Finance, Government, Healthcare, and Transportation) and ... the market is expected to be worth USD 8.49 ... between 2015 and 2020. The transformation and technology evolution ...
Breaking Biology News(10 mins):